📊 CRVO Key Takeaways
Investment Thesis
CervoMed is a pharmaceutical company in severe financial distress with dramatically deteriorating fundamentals. Revenue collapsed 58.9% YoY to just $4.0M while operating losses expanded to -$28.3M, indicating the company is burning cash at an unsustainable rate with no clear path to profitability. Despite adequate near-term liquidity, the company's burn rate of -$23.4M in operating cash flow against minimal revenue suggests runway of approximately 5 months at current levels.
CRVO Strengths
- Strong current ratio of 4.91x provides near-term liquidity cushion
- No long-term debt reduces financial obligations and restructuring complexity
- Cash reserves of $8.2M provide some runway for operations or strategic pivots
CRVO Risks
- Massive operating losses of -$28.3M against $4.0M revenue indicates core business failure
- Operating cash burn of -$23.4M annually with only $8.2M cash will exhaust liquidity in ~3-5 months without capital injection
- Zero gross profit and 0% gross margin indicate product offerings generate no value or are not selling
- Severe negative profitability margins (-706% operating margin, -673% net margin) reflect fundamental business model breakdown
- Revenue decline of 58.9% YoY demonstrates accelerating commercial failure, not temporary headwinds
Key Metrics to Watch
- Monthly operating cash burn rate and runway calculation
- Revenue stabilization and customer acquisition trends
- Gross margin improvement indicating product viability
- Insider trading activity suggesting management confidence or exit strategy
CRVO Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 4.91x current ratio provides a solid financial cushion.
CRVO Profitability Ratios
CRVO vs Healthcare Sector
How CervoMed Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CRVO Balance Sheet & Liquidity
CRVO 5-Year Financial Trend
5-Year Trend Summary: CervoMed Inc.'s revenue has grown significantly by 36% over the 5-year period, indicating strong business expansion. The most recent EPS of $1,946,859.00 reflects profitable operations.
CRVO Growth Metrics (YoY)
CRVO Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $322.6K | -$4.8M | N/A |
| Q2 2025 | $1.8M | -$2.3M | N/A |
| Q1 2025 | $1.9M | -$2.5M | N/A |
| Q3 2024 | $1.5M | $190.5K | $-0.55 |
| Q2 2024 | $1.7M | -$1.4M | N/A |
| Q1 2024 | $1.4M | -$534.3K | N/A |
| Q3 2023 | N/A | $190.5K | $-0.70 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CRVO Capital Allocation
CRVO SEC Filings
Access official SEC EDGAR filings for CervoMed Inc. (CIK: 0001053691)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CRVO
What is the AI rating for CRVO?
CervoMed Inc. (CRVO) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CRVO's key strengths?
Strong current ratio of 4.91x provides near-term liquidity cushion. No long-term debt reduces financial obligations and restructuring complexity.
What are the risks of investing in CRVO?
Massive operating losses of -$28.3M against $4.0M revenue indicates core business failure. Operating cash burn of -$23.4M annually with only $8.2M cash will exhaust liquidity in ~3-5 months without capital injection.
What is CRVO's revenue and growth?
CervoMed Inc. reported revenue of $4.0M.
Does CRVO pay dividends?
CervoMed Inc. does not currently pay dividends.
Where can I find CRVO SEC filings?
Official SEC filings for CervoMed Inc. (CIK: 0001053691) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CRVO's EPS?
CervoMed Inc. has a diluted EPS of $-1.22.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.